FDA cites two European companies in separate warning letters

lab

The FDA named two European drug manufacturers--Delarange Cosmetics & Healthcare of the Netherlands and Wallace Cameron of the U.K.--in separate warning letters, citing poor quality control, filthy equipment and failure to register with the agency.

In the case of Delarange, the FDA said in a warning letter recently posted on its website that during an inspection that ran from May 30 to June 3 of its facility in Zeewolde, it found the firm wasn’t testing its finished products and wasn’t using a quality control unit to review and approve the release of its drugs.

Additionally, inspectors found Delarange wasn’t properly cleaning the equipment, which could result in product contamination.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

As for Wallace Cameron, located in Wishaw, Scotland, the regulatory agency scolded the firm for failing to register and list its products with the FDA.

“Our records indicate that you have not registered your establishment for 2016, but have continued to manufacture, prepare, propagate, compound, or process drugs that were not listed but being imported or offered for import into the United States during this time,” the agency says in its warning.

The drug manufactured at Wallace Cameron wasn’t mentioned by the agency.

- here’s the Delarange warning letter
- check out the Wallace Cameron warning letter

Related Article:
FDA slaps CordenPharma EU plant with warning letter

Suggested Articles

Pfizer says two lots of migraine med Relpax failed to meet microbial standards and may be contaminated with genera pseudomonas and burkholderia.

Emcure has had its share of run-ins with the FDA in the past over the sterility of its plants. Now, it can notch one more black mark on its belt.

The FDA has slapped a warning letter on an Indian solvent recycler that may have contributed to the contamination of blood pressure meds.